HomepageIMC ⢠ASX
add
Immuron Ltd
Vorige slotkoers
$Ā 0,038
Dag-range
$Ā 0,035 - $Ā 0,036
Jaar-range
$Ā 0,034 - $Ā 0,10
Beurswaarde
11,76Ā mln. AUD
Gem. volume
1,35Ā mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
ASX
Marktnieuws
Financiƫle informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (AUD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,65Ā mln. | 29,26% |
Bedrijfskosten | 2,46Ā mln. | -0,53% |
Netto inkomsten | -1,36Ā mln. | 43,93% |
Netto winstmarge | -82,83 | 56,62% |
Winst per aandeel | ā | ā |
EBITDA | -1,40Ā mln. | 11,97% |
Effectief belastingtarief | ā | ā |
Balans
Totale activa
Totale passiva
| (AUD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 5,87Ā mln. | -49,67% |
Totale activa | 10,13Ā mln. | -34,86% |
Totale passiva | 2,06Ā mln. | -27,45% |
Totaal aandelenvermogen | 8,07Ā mln. | ā |
Uitstaande aandelen | 268,22Ā mln. | ā |
Koers-boekwaardeverhouding | 1,27 | ā |
Rendement op activa | -34,77% | ā |
Rendement op kapitaal | -43,03% | ā |
Kasstroom
Nettomutatie in liquide middelen
| (AUD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -1,36Ā mln. | 43,93% |
Operationele kasstroom | -1,07Ā mln. | 44,70% |
Kasstroom uit beleggingen | -1,48Ā mln. | -1.797,41% |
Kasstroom uit financiering | 120,82K | 906,88% |
Nettomutatie in liquide middelen | -2,45Ā mln. | -37,95% |
Vrije kasstroom | -704,67K | 27,75% |
Over
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Opgericht
1994
Hoofdvestiging
Website
Werknemers
7